https://doi.org/10.4081/itjm.2021.1351

Treatment and secondary prophylaxis of venous thromboembolism with direct oral anticoagulants in patients with severe hereditary thrombophilia

Vol. 15 No. 1 (2021)
Submitted: 1 August 2020
Accepted: 6 October 2020
Published: 18 March 2021
Venous thromboembolism, hereditary thrombophilia, direct oral anticoagulants.
Abstract Views: 1099
PDF: 520
HTML: 54
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Pasquale Madonna
linomadonna@libero.it
https://orcid.org/0000-0003-3637-3055
U.O.C. Medicina Interna, P.O. Ospedale del Mare, ASL NA 1 Centro, Napoli, Italy.
Anna Guida
https://orcid.org/0000-0003-4730-9649
U.O.C. Medicina Interna, P.O. Ospedale del Mare, ASL NA 1 Centro, Napoli, Italy.
Maria Gabriella Coppola
https://orcid.org/0000-0003-0834-7546
U.O.C. Medicina Interna, P.O. Ospedale del Mare, ASL NA 1 Centro, Napoli, Italy.
Paolo Tirelli
https://orcid.org/0000-0001-6115-6015
U.O.C. Medicina Interna, P.O. Ospedale del Mare, ASL NA 1 Centro, Napoli, Italy.
Ernesto Grasso
U.O.C. Medicina Interna, P.O. Ospedale del Mare, ASL NA 1 Centro, Napoli, Italy.

Deficiency of protein C (PC), protein S (PS), antithrombin III (AT III), and homozygosity or combined heterozygosity for Factor V Leiden (FVL) and Factor II (FII) 20210A mutation represent severe hereditary thrombophilia (SHT) and are associated with a higher risk of early-onset venous thromboembolism (VTE). In literature, few papers have described the efficacy and safety of therapy with direct oral anticoagulants (DOACs) in VTE occurring in patients with SHT. In our setting, we identified 8 patients who have suffered from early-onset VTE and underwent therapy with DOACs (6 rivaroxaban, 2 apixaban). Among them, 2 AT III deficiency, 2 PC deficiency, 3 PS deficiency, 1 combined heterozygosity for FVL, and FII 20210A were detected. During the follow-up, neither recurrences of VTE nor hemorrhagic episodes were observed. This report describes the efficacy and safety of therapy with anti-Xa in the treatment and secondary prophylaxis of VTE in patients with SHT.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost 2015;114:885-9. DOI: https://doi.org/10.1160/TH15-02-0141
Franchini M, Veneri D, Salvagno GL, et al. Inherited thrombophilia. Crit Rev Clin Lab Sci 2006;43:249-90. DOI: https://doi.org/10.1080/10408360600552678
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808. DOI: https://doi.org/10.1056/NEJMoa1302507
Einstein Investigators; Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510. DOI: https://doi.org/10.1056/NEJMoa1007903
van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968-75. DOI: https://doi.org/10.1182/blood-2014-04-571232
Undas A, Goralczyk T. Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients. Blood Coagul Fibrinol 2017;28:438-42. DOI: https://doi.org/10.1097/MBC.0000000000000613
Schulman S, Eriksson H, Goldhaber S, et al. Influence of thrombophilia on the efficacy of dabigatran versus warfarin for the extended treatment of acute venous thromboembolism in RE-MEDYâ„¢. Blood 2014;124:A1544. DOI: https://doi.org/10.1182/blood.V124.21.1544.1544
Alameddinea R, Nassabeina R, Le Galb G, et al. Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants. Thromb Res 2020;185:72-7. DOI: https://doi.org/10.1016/j.thromres.2019.11.008
Wypasek E, Potaczek DP, Alhenc-Gelas M, Undas A. PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy. Thromb Res 2014;134:199-201. DOI: https://doi.org/10.1016/j.thromres.2014.01.023
Boey JP, Jolley A, Nicholis C, et al. Novel protein C gene mutation in a compound heterozygote resulting in cathastrophic thrombosis in early adulthood: diagnosis and long-term treatment with subcutaneous protein C concentrate. Br J Haematol 2016;172:811-3. DOI: https://doi.org/10.1111/bjh.13538
Hermans C, Eeckhoudt S, Lambert C. Dabigatran etexilate (Pradaxa(R)) for preventing warfarin-induced skin necrosis in a patient with severe protein C deficiency. Thromb Haemost 2012;107:1189-91. DOI: https://doi.org/10.1160/TH11-11-0788

How to Cite

Madonna, P., Guida, A., Coppola, M. G., Tirelli, P., & Grasso, E. (2021). Treatment and secondary prophylaxis of venous thromboembolism with direct oral anticoagulants in patients with severe hereditary thrombophilia. Italian Journal of Medicine, 15(1). https://doi.org/10.4081/itjm.2021.1351

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.